| Selective estrogen receptor modulator | |
|---|---|
| Drug class | |
 Tamoxifen, a nonsteroidal triphenylethylene antiestrogen and a widely used drug in the treatment of breast cancer. | |
| Class identifiers | |
| Synonyms | SERM; Estrogen receptor agonist/antagonist; ERAA |
| Use | Breast cancer, infertility, osteoporosis, vaginal atrophy, dyspareunia, contraception, male hypogonadism, gynecomastia, breast pain, others |
| ATC code | G03XC |
| Biological target | Estrogen receptor |
| Legal status | |
| In Wikidata | |
Selective estrogen receptor modulators (SERMs), also known as estrogen receptor agonists/antagonists (ERAAs),[1][2] are a class of drugs that act on estrogen receptors (ERs).[3] Compared to pure ER agonists–antagonists (e.g., full agonists and silent antagonists), SERMs are more tissue-specific, allowing them to selectively inhibit or stimulate estrogen-like action in various tissues.
- ^ Hirsch HD, Shih E, Thacker HL (June 2017). "ERAAs for menopause treatment: Welcome the 'designer estrogens'". Cleve Clin J Med. 84 (6): 463–470. doi:10.3949/ccjm.84a.15140. PMID 28628428.
- ^ Archer DF (August 2020). "Ospemifene: less venous thrombosis than other selective estrogen receptor modulators in postmenopausal women with vulvo vaginal atrophy". Menopause. 27 (8): 846–847. doi:10.1097/GME.0000000000001600. PMID 32576803. S2CID 220045301.
- ^ Riggs BL, Hartmann LC (Feb 2003). "Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice". The New England Journal of Medicine. 348 (7): 618–29. doi:10.1056/NEJMra022219. PMID 12584371.